APA (7th ed.) Citation

Hirozumi Sano, Ryoji Kobayashi, Satoru Matsushima, Daiki Hori, Masato Yanagi, Koya Kodama, . . . Kunihiko Kobayashi. (2021). Comparison of the Efficacy of Piperacillin/Tazobactam and Meropenem, with or without Intravenous Immunoglobulin, as Second-Line Therapy for Febrile Neutropenia: A Prospective, Randomized Study. The Korean Society of Pediatric Hematology-Oncology.

Chicago Style (17th ed.) Citation

Hirozumi Sano, Ryoji Kobayashi, Satoru Matsushima, Daiki Hori, Masato Yanagi, Koya Kodama, Daisuke Suzuki, and Kunihiko Kobayashi. Comparison of the Efficacy of Piperacillin/Tazobactam and Meropenem, with or Without Intravenous Immunoglobulin, as Second-Line Therapy for Febrile Neutropenia: A Prospective, Randomized Study. The Korean Society of Pediatric Hematology-Oncology, 2021.

MLA (9th ed.) Citation

Hirozumi Sano, et al. Comparison of the Efficacy of Piperacillin/Tazobactam and Meropenem, with or Without Intravenous Immunoglobulin, as Second-Line Therapy for Febrile Neutropenia: A Prospective, Randomized Study. The Korean Society of Pediatric Hematology-Oncology, 2021.